Shots:
- The company has applied for emergency use authorization to the DCGI for ZyCoV-D, which is the world’s first plasmid DNA vaccine for COVID-19
- Zydus conducted a clinical trial for its ZyCoV-D in the adolescent population aged 12-18yrs. in India over 50 centers. The vaccine is safe and well-tolerated and showed 66% efficacy for symptomatic RT-PCR positive cases.
- The vaccine reaffirms its efficacy against the new mutant strains especially the delta variant. ZyCoV-D is a three-dose, intradermal vaccine, and is needle-free, leading to a reduction in any side effects. The company plans to manufacture 10-12 crore doses annually
Click here to read full press release/ article | Ref: Zydus | Image: PR Newswire
The post Zydus Seeks EUA for ZyCoV-D Against COVID-19 in India first appeared on PharmaShots.
